Insulin analogues: Action profiles beyond glycaemic control

Archives of Physiology and Biochemistry

Volumn 114, Issue 1, 2008, Pages 45-53

  Eckardt, Kristin ^a   Eckel, Jürgen ^a  

^a LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

Author keywords

IGF 1 receptor; Insulin analogues; Insulin glargine; Mitogenic signalling

Indexed keywords

DRUG DERIVATIVE; INSULIN;

ANIMAL; CELL PROLIFERATION; DIABETES MELLITUS; DRUG EFFECT; GLUCOSE BLOOD LEVEL; HUMAN; METABOLISM; REVIEW; SIGNAL TRANSDUCTION; TIME;

ANIMALS; BLOOD GLUCOSE; CELL PROLIFERATION; DIABETES MELLITUS; HUMANS; INSULIN; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 47349113215     PISSN: 13813455     EISSN: 17444160     Source Type: Journal    
DOI: 10.1080/13813450801983369     Document Type: Review

References (90)

1. Anderson JH, Jr., Brunelle RL, Koivisto VA, Pfutzner A, Trautmann ME, Vignati L, DiMarchi R. 1997. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 46:265-70.
2. Barnett AH. 2006. How well do rapid-acting insulins work in obese individuals? Diabetes Obes Metab 8:388-95.
3. Becker RH, Frick AD, Burger F, Potgieter JH, Scholtz H. 2005. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 113:435-43.
4. Berti L, Kellerer M, Bossenmaier B, Seffer E, Seipke G, Haring HU. 1998. The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm Metab Res 30:123-9.
5. Bornfeldt KE, Gidlof RA, Wasteson A, Lake M, Skottner A, Arnqvist HJ. 1991. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Comparison of maximal growth promoting activities. Diabetologia 34:307-13.
6. Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G. 2003. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care 26:1390-4.
7. Brunelle BL, Llewelyn J, Anderson JH, Jr., Gale EA, Koivisto VA. 1998. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 21:1726-31.
8. Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR. 2000. Role of brain insulin receptor in control of body weight and reproduction. Science 289:2122-5.
9. Brunner GA, Hirschberger S, Sendlhofer G, Wutte A, Ellmerer M, Balent B, Schaupp L, Krejs GJ, Pieber TR. 2000a. Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus. Diabet Med 17:371-5.
10. Brunner GA, Sendhofer G, Wutte A, Ellmerer M, Sogaard B, Siebenhofer A, Hirschberger S, Krejs GJ, Pieber TR. 2000b. Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin Endocrinol Diabetes 108:100-5.
11. Brunton SA. 2007. Nocturnal Hypoglycemia: Answering the Challenge With Long-acting Insulin Analogs. MedGenMed 9:38.
12. Calle-Pascual AL, Bagazgoitia J, Calle JR, Charro A, Maranes JP. 2000. Use of insulin lispro in pregnancy. Diabetes Nutr Metab 13:173-7.
13. Chapman TM, Perry CM. 2005. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus. BioDrugs 19:67-69.
14. Ciaraldi TP, Carter L, Seipke G, Mudaliar S, Henry RR. 2001. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I. J Clin Endocrinol Metab 86:5838-47.
15. Ciaraldi TP, Phillips SA, Carter L, Aroda V, Mudaliar S, Henry RR. 2005. Effects of the rapid-acting insulin analog glulisine on cultured human skeletal muscle cells: Comparisons with insulin and insulin-like growth factor I. J Clin Endocrinol Metab 90:5551-8.
16. Dailey G, Rosenstock J, Moses RG, Ways K. 2004. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27:2363-8.
17. Di Cianni G, Volpe L, Ghio A, Lencioni C, Cuccuru I, Benzi L, Del Prato S. 2007. Maternal metabolic control and perinatal outcome in women with gestational diabetes mellitus treated with lispro or aspart insulin: comparison with regular insulin. Diabetes Care 30:e11.
18. Dornhorst A, Luddeke HJ, Honka M, Ackermann RW, Merilainen M, Gallwitz B, Sreenan S, Group OB. 2007. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin 24:369-76.
19. Drejer K. 1992. The bioactivity of insulin analogues from in vitro receptor binding to in vivo glucose uptake. Diabetes Metab Rev 8:259-85.
20. Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, Van Leendert R. 2005. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 37:702-7.
21. Duckworth W, Davis SN. 2007. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. J Diabetes Complications 21:196-204.
22. Eckardt K, May C, Koenen M, Eckel J. 2007. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts. Diabetologia 50:2534-43.
23. Eckel J. 2005. Insulin analogs revisited. Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents 5:475-84.
24. Ellmerer M, Schaupp L, Brunner GA, Sendlhofer G, Wutte A, Wach P, Pieber TR. 2000. Measurement of interstitial albumin in human skeletal muscle and adipose tissue by open-flow microperfusion. Am J Physiol Endocrinol Metab 278:E352-6.
25. Fulcher GR, Gilbert RE, Yue DK. 2005. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J 35:536-42.
26. Galloway JA, Chance RE. 1994. Improving insulin therapy: achievements and challenges. Horm Metab Res 26:591-8.
27. Garg SK, Anderson JH, Gerard LA, Mackenzie TA, Gottlieb PA, Jennings MK, Chase HP. 2000. Impact of insulin lispro on HbA1c values in insulin pump users. Diabetes Obes Metab 2:307-11.
28. Garg SK, Frias JP, Anil S, Gottlieb PA, MacKenzie T, Jackson WE. 2003. Insulin lispro therapy in pregnancies complicated by type 1 diabetes: glycemic control and maternal and fetal outcomes. Endocr Pract 9:187-93.
29. Garg SK, Rosenstock J, Ways K. 2005. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine. Endocr Pract 11:11-17.
30. Gerich J, Becker RH, Zhu R, Bolli GB. 2006. Fluctuation of serum Basal insulin levels following single and multiple dosing of insulin glargine. Diabetes Technol Ther 8:237-43.
31. Griffen SC, Oostema K, Stanhope KL, Graham J, Styne DM, Glaser N, Cummings DE, Connors MH, Havel PJ. 2006. Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes. J Clin Endocrinol Metab 91:485-91.
32. Havelund S, Plum A, Ribel U, Jonassen I, Volund A, Markussen J, Kurtzhals P. 2004. The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 21:1498-504.
33. Haycox A. 2004. Insulin aspart: an evidence-based medicine review. Clin Drug Investig 24:695-717.
34. Hedman CA, Lindstrom T, Arnqvist HJ. 2001. Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes. Diabetes Care 24:1120-1.
35. Heinemann L, Starke AA, Hohmann A, Berger M. 1992. Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm Metab Res Suppl 26:137-9.
36. Heise T, Nosek L, Spitzer H, Heinemann L, Niemoller E, Frick AD, Becker RH. 2007. Insulin glulisine: a faster onset of action compared with insulin lispro. Diabetes Obes Metab 9:746-53.
37. Heller SR, Amiel SA, Mansell P. 1999. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care 22:1607-11.
38. Hennige AM, Lehmann R, Weigert C, Moeschel K, Schauble M, Metzinger E, Lammers R, Haring HU. 2005a. Insulin glulisine: insulin receptor signaling characteristics in vivo. Diabetes 54:361-6.
39. Hennige AM, Sartorius T, Tschritter O, Preissl H, Fritsche A, Ruth P, Haring HU. 2006. Tissue selectivity of insulin detemir action in vivo. Diabetologia 49:1274-82.
40. Hennige AM, Strack V, Metzinger E, Seipke G, Haring HU, Kellerer M. 2005b. Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors. Diabetologia 48:1891-97.
41. Hod M, Damm P, Kaaja R, Visser GH, Dunne F, Demidova I, Hansen AS, Mersebach H. 2007. Fetal and perinatal outcomes in type 1 diabetes pregnancy: a randomized study comparing insulin aspart with human insulin in 322 subjects. Am J Obstet Gynecol 198:186.e1-186.e7.
42. Holcberg G, Tsadkin-Tamir M, Sapir O, Wiznizer A, Segal D, Polachek H, Ben Zvi Z. 2004. Transfer of insulin lispro across the human placenta. Eur J Obstet Gynecol Reprod Biol 115:117-18.
43. Homko C, Deluzio A, Jimenez C, Kolaczynski JW, Boden G. 2003. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care 26:2027-31.
44. Homko CJ, Reece EA. 2006. Insulins and oral hypoglycemic agents in pregnancy. J Matern Fetal Neonatal Med 19:679-86.
45. Hordern SV, Wright JE, Umpleby AM, Shojaee-Moradie F, Amiss J, Russell-Jones DL. 2005. Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp. Diabetologia 48:420-6.
46. Howey DC, Bowsher RR, Brunelle RLWoodworth JR.. 1994. [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin. Diabetes 43:396-402.
47. Kacerovsky-Bielesz G, Dressler A, Freunscht R. 2005. Long-term glycaemic control with insulin glargine in Type 2 diabetes. Diabetes Res Clin Pract 71:184-91.
48. Kaiyala KJ, Prigeon RL, Kahn SE, Woods SC, Schwartz MW. 2000. Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 49:1525-33.
49. Knott GW, Dziegielewska KM, Habgood MD, Li ZS, Saunders NR. 1997. Albumin transfer across the choroid plexus of South American opossum (Monodelphis domestica). J Physiol 499(1):179-94.
50. Koster I, von Ferber L, Ihle P, Schubert I, Hauner H. 2006. The cost burden of diabetes mellitus: The evidence from Germany - the CoDiM study. Diabetologia 49:1498-1504.
51. Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, Trub T. 2000. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 49:999-1005.
52. Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A, Cordoni C, Costa E, Brunetti P, Bolli GB. 2000. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142-8.
53. Lindholm A, McEwen J, Riis AP. 1999. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes. Diabetes Care 22:801-5.
54. Lingohr MK, Dickson LM, McCuaig JF, Hugl SR, Twardzik DR, Rhodes CJ. 2002. Activation of IRS-2-mediated signal transduction by IGF-1, but not TGF-alpha or EGF, augments pancreatic beta-cell proliferation. Diabetes 51:966-76.
55. Luzio S, Peter R, Dunseath GJ, Mustafa L, Owens DR. 2007. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. Diabetes Res Clin Pract 79:269-75.
56. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrom J, Hasselager E, Larsen UD, Ribel U, Schaffer L, Vad K, Jonassen I. 1996. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39:281-8.
57. Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, Bellaire S, Raben A. 2007. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: A randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 30:771-6.
58. Melki V, Renard E, Lassmann-Vague V, Boivin S, Guerci B, Hanaire-Broutin H, Bringer J, Belicar P, Jeandidier N, Meyer L, Blin P, Augendre-Ferrante B, Tauber JP. 1998. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 21:977-82.
59. Murase Y, Yagi K, Sugihara M, Chujo D, Otsuji M, Muramoto H, Mabuchi H. 2004. Lispro is superior to regular insulin in transient intensive insulin therapy in type 2 diabetes. Intern Med 43:779-86.
60. Perriello G, Pampanelli S, Porcellati F, Avogaro A, Bosi E, Petrella G, Squatrito S, Furneri S, Marra G, Vitali L, Previti M, Cucinotta D. 2005. Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: A randomized, stratified, double-blind and cross-over trial. Diabetic Medicine 22:606-11.
61. Pfutzner A, Kustner E, Forst T, Schulze-Schleppinghoff B, Trautmann ME, Haslbeck M, Schatz H, Beyer J. 1996. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 104:25-30.
62. Pieber TR, Treichel HC, Hompesch B, Philotheou A, Mordhorst L, Gall MA, Robertson LI. 2007. Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabet Med 24:635-42.
63. Plank J, Bodenlenz M, Sinner F, Magnes C, Gorzer E, Regittnig W, Endahl LA, Draeger E, Zdravkovic M, Pieber TR. 2005. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28:1107-12.
64. Porte Jr. D. 2006. Central regulation of energy homeostasis: the key role of insulin. Diabetes 55 Suppl 2: S155-60.
65. Rakatzi I, Ramrath S, Ledwig D, Dransfeld O, Bartels T, Seipke G, Eckel J. 2003a. A novel insulin analog with unique properties: LysB3,GluB29 insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 52:2227-38.
66. Rakatzi I, Seipke G, Eckel J. 2003b. [LysB3, GluB29] insulin: a novel insulin analog with enhanced beta-cell protective action. Biochem Biophys Res Commun 310:852-9.
67. Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, Mecca T. 2000. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 23:1666-71.
68. Raslova K, Tamer SC, Clauson P, Karl D. 2007. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 27:279-85.
69. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. 1999. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 22:784-8.
70. Rhodes CJ. 2005. Type 2 diabetes - a matter of beta-cell life and death? Science 307:380-4.
71. Riddle MC, Rosenstock J, Gerich J. 2003. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26:3080-6.
72. Rosenfalck AM, Thorsby P, Kjems L, Birkeland K, Dejgaard A, Hanssen KF, Madsbad S. 2000. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 37:41-6.
73. Rosenstock J, Park G, Zimmerman J. 2000. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 23:1137-42.
74. Rosenstock J, Schwartz SL, Clark CM, Jr., Park GD, Donley DW, Edwards MB. 2001. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 24:631-6.
75. Rossetti P, Porcellati F, Busciantella RN, Candeloro P, Cioli P, Bolli GB, Fanelli GG. 2007. Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans. Diabetes 57:746-56.
76. Schwartz MW, Woods SC, Porte D, Jr., Seeley RJ, Baskin DG. 2000. Central nervous system control of food intake. Nature 404:661-71.
77. Seyfert S, Kunzmann V, Schwertfeger N, Koch HC, Faulstich A. 2002. Determinants of lumbar CSF protein concentration. J Neurol 249:1021-26.
78. Shymko RM, Dumont E, De Meyts P, Dumont JE. 1999. Timing-dependence of insulin-receptor mitogenic versus metabolic signalling: a plausible model based on coincidence of hormone and effector binding. Biochem J 339(3):675-83.
79. Slieker LJ, Brooke GS, DiMarchi RD, Flora DB, Green LK, Hoffmann JA, Long HB, Fan L, Shields JE, Sundell KL, Surface PL, Chance RE. 1997. Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 40:S54-61.
80. Staiger K, Staiger H, Schweitzer MA, Metzinger E, Balletshofer B, Haring HU, Kellerer M. 2005. Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia 48:1898-1905.
81. Stammberger I, Seipke G, Bartels T. 2006. Insulin glulisine-a comprehensive preclinical evaluation. Int J Toxicol 25:25-33.
82. The Diabetes Control and Complications Trial Research Group.1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-86.
83. Tibaldi J. 2007. Actions of insulin beyond glycemic control: A perspective on insulin detemir. Adv Ther 24:868-82.
84. Torlone E, Fanelli C, Rambotti AM, Kassi G, Modarelli F, Di Vincenzo A, Epifano L, Ciofetta M, Pampanelli S, Brunetti P. 1994. Pharmacokinetics, pharmacodynamics and glucose counterregulation following subcutaneous injection of the monomeric insulin analogue [Lys(B28), Pro(B29)] in IDDM. Diabetologia 37:713-20.
85. Tschritter O, Hennige AM, Preissl H, Porubska K, Schafer SA, Lutzenberger W, Machicao F, Birbaumer N, Fritsche A, Haring HU. 2007. Cerebrocortical Beta activity in overweight humans responds to insulin detemir. PLoS ONE 2:e1196.
86. UK Prospective Diabetes Study (UKPDS) Group.1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). The Lancet 352:837-53.
87. Vajo Z, Fawcett J, Duckworth WC. 2001. Recombinant DNA technology in the treatment of diabetes: Insulin analogs. Endocr Rev 22:706-17.
88. White MF. 1997. The insulin signalling system and the IRS proteins. Diabetologia 40:S2-17.
89. Woods SC, Seeley RJ, Baskin DG, Schwartz MW. 2003. Insulin and the blood-brain barrier. Curr Pharm Des 9:795-800.
90. Yki-Jarvinen H, Dressler A, Ziemen M. 2000. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetesHOE 901/3002 Study Group. Diabetes Care 23:1130-6.